Growth Metrics

Crescent Biopharma (CBIO) Revenue (2013 - 2026)

Crescent Biopharma (CBIO) reported Revenue of $1.0 million for Q1 2026, up 1285.33% on a QoQ basis from $75000.0 in Q2 2022.

Crescent Biopharma (CBIO) has 8 years of Revenue data on file, last reported at $1.0 million in Q1 2026.

  • Quarterly Revenue changed N/A year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (changed N/A YoY) and the FY2025 annual result came in at $10.8 million, changed N/A from the prior year.
  • Revenue improved to $1.0 million in Q1 2026 per CBIO's latest filing, from $75000.0 in the prior quarter.
  • Across five years, Revenue topped out at $1.0 million in Q1 2026 and bottomed at $75000.0 in Q2 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn 306.30 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn 2.99 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn 3.61 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn 1.17 Bn
10 Crescent Biopharma 569.36 Mn 380.20 Mn - 1.04 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 1.04 Mn
Jun 30, 2022 75,000.00
Dec 31, 2021 17,625.00
Sep 30, 2021 86,560.00
Jun 30, 2021 142.00
Mar 31, 2021 1.06 Mn
Dec 31, 2020 162,935.00
Sep 30, 2020 1.00 Mn
Mar 31, 2020 9.00 Mn
Sep 30, 2016 18,500.00
Dec 31, 2015 35,375.00
Sep 30, 2015 35,375.00
Jun 30, 2015 20.00 Mn
Jun 30, 2014 15.03 Mn
Dec 31, 2013 77,413.00
Sep 30, 2013 52,571.00
Jun 30, 2013 55,074.00
Mar 31, 2013 3.81 Mn